We have been exploring the role of iron in the pathogenesis of the intracellular bacterial pathogen Legionella pneumophila In previous studies, we have demonstrated that L. pneumophila intracellular multiplication in human monocytes is iron dependent and that IFN-y-activated monocytes inhibit L. pneumophila intracellular multiplication by limiting the availability of iron. In this study, we have investigated the effect on L. pneumophila intracellular multiplication of lactoferrin, an ironbinding protein which is internalized via specific receptors on monocytes, and of nonphysiologic iron chelates which enter monocytes by a receptor-independent route.
Introduction
Iron plays an important role in the energy metabolism ofmicroorganisms including those pathogenic for humans. In the case of extracellular bacterial pathogens, iron has been shown to enhance virulence (1) . In the human body, iron is relatively unavailable extracellularly as it is bound to the high-affinity iron-binding proteins transferrin and lactoferrin. To obtain iron, extracellular bacteria have evolved mechanisms, such as siderophores and siderophore receptors (2) , receptors for ironsaturated transferrin (3), or receptors for iron-saturated lactoferrin (4) , that allow them to remove and utilize iron from iron-binding proteins.
Whereas much has been learned about iron acquisition by extracellular pathogens, relatively little is known about iron acquisition by intracellular pathogens. We have been exploring some aspects of this subject using the intracellular bacterial pathogen Legionella pneumophila. This pathogen multiplies intracellularly in human mononuclear phagocytes; in the lung, it parasitizes alveolar macrophages and causes Legionnaires' disease. Cell-mediated immunity plays a major role in host defense against L. pneumophila, and activated monocytes and alveolar macrophages, including those activated by interferon gamma (IFNy)' inhibit L. pneumophila intracellular multiplication (5, 6) . As multiplication of L. pneumophila is exclusively intracellular under tissue culture conditions (7) , this organism is ideal for studies ofiron acquisition by an intracellular pathogen, and of the role of iron in macrophage activation.
In previous studies, we have determined that L. pneumophila intracellular multiplication is iron dependent (8) . We have also found that IFNy-activated monocytes inhibit L. pneumophila intracellular multiplication by limiting the availability of intracellular iron (8) . Our studies have revealed two mechanisms by which IFNy-activated monocytes may accomplish this. First, they markedly downregulate transferrin receptors which bind and endocytize iron-saturated transferrin (8) ; the transferrin-transferrin receptor endocytic pathway is the major physiologic conduit for iron into the cell. Second, IFNyactivated monocytes downregulate the concentration of intracellular ferritin (9) , the major iron storage protein in the cell and a readily available source of mobilizable iron.
In the present study, we have explored the role of lactoferrin in L. pneumophila-monocyte interaction. Lactoferrin, like transferrin, is an iron binding protein in the human body which can increase the level of mononuclear phagocyte intracellular iron (10-12). Lactoferrin is felt to play an important role in host defense by acting to withhold iron from pathogenic bacteria during infection (13) . By binding iron and then being internalized by mononuclear phagocytes, lactoferrin may contribute to the decrease in serum iron, the so-called hypoferremic response, seen in infection or inflammatory states (14) . Although the effect of lactoferrin on the multiplication of extracellular pathogens has been well described (1) , its effect on the multiplication of intracellular pathogens has not. In contrast to iron-saturated transferrin, which enters a nonlysosomal intracellular compartment of the cell which has approximately the same relatively high pH as the L. pneumophila phagosome (-6.3) (15, 16) , iron-saturated lactoferrin enters a lysosomal intracellular compartment of relatively low pH (< 5) (10-12). Because of these differences in the endocytic pathways of lactoferrin and transferrin, we wondered whether L. pneumophila would have access to iron derived from ironlactoferrin as it does to iron derived from iron-transferrin.
In contrast to transferrin receptors, which have a low affinity for apotransferrin, lactoferrin receptors have a high affinity for apolactoferrin, which is evidently endocytized as efficiently as iron-saturated lactoferrin (17, 18) . We therefore wondered whether apolactoferrin, a physiologic iron chelator, would act to limit the availability of iron to intracellular L. pneumophila in monocytes as does the nonphysiologic iron chelator deferoxamine.
Our studies shall show that L. pneumophila can utilize iron delivered into the infected monocyte via the lactoferrin-lactoferrin receptor endocytic pathway and that iron-saturated lactoferrin can reverse the capacity of IFNy-activated monocytes to inhibit L. pneumophila intracellular multiplication. 20 ,000 U/ml) (Genentech, Inc., South San Francisco, CA) or control buffer (PBS-BSA). Nonactivated monocytes were incubated with iron-saturated lactoferrin (6 mg/ ml) or apolactoferrin (2-3 mg/ml). IFNy-treated cultures were incubated with iron lactoferrin (0.07-6 mg/ml; 28%, 51%, or 90% iron saturated), apolactoferrin (2 mg/ml), FeNTA (3.4-112 Mg/mi; 0. ,ug iron/ml), NTA (87 Ag/ml), ferric ammonium citrate (8 and 25 ,g iron/ml), ferric pyrophosphate (8 and 25 gg iron/ml) or control buffer. After 24 h, L. pneumophila (104 CFU/ml) were added to the monocyte cultures. The cultures were then incubated at 370C in 5% C02-95% air 1104 T. F. Byrd and M. A. Horwitz on a gyratory shaker (100 rpm) for 1 h and under stationary conditions thereafter. CFU of L. pneumophila in each culture were determined daily as described (7) . At the end of each experiment, the viability of monocytes was assayed by trypan blue exclusion. All experiments were run in triplicate.
In some experiments, L. pneumophila were preincubated with or without apolactoferrin (3 mg/ml) in 0.5 ml RPMI containing 20% fresh normal human serum in 5% C02-95% air at 370C for 24 h. The bacteria were then washed thoroughly, resuspended in RPMI and added to monocyte cultures as in the experiments described above.
In experiments conducted under serumless conditions, freshly explanted monocytes were adhered to Linbro flat-bottomed wells in the presence of serum and then vigorously washed five times with Iscoves modified Dulbeccos medium (Gibco) to remove nonadherent cells and serum. The monocyte monolayers, containing -5 X 10' cells, were then incubated in 0.5 ml of Iscoves medium at 370C in 5% C02-95% air in the presence of IFN'y (2 yg/ml) or control buffer (PBS-BSA).
Monocytes treated with IFN-y were also incubated with iron lactoferrin (3 mg/ml), ferric ammonium citrate (25 ;&g iron/ml) or control media.
After 24 h, the monocyte monolayers were infected with preopsonized L. pneumophila that had been incubated in 20% autologous normal human serum (NHS) for 30 min, washed twice by centrifugation at 15,000 g for 5 min in a refrigerated microcentrifuge (Savant Instruments, Inc., Hicksville, NY), and resuspended in Iscoves medium. CFU of L. pneumophila in each triplicate culture were determined as above.
Results
Apolactoferrin inhibits L. pneumophila intracellular multiplication in nonactivated monocytes. L. pneumophila intracellular multiplication is iron dependent, and consequently, the ironchelator deferoxamine inhibits L. pneumophila multiplication in human monocytes (8) . To determine if apolactoferrin, a physiologic iron chelator recognized by lactoferrin receptors, also inhibits L. pneumophila multiplication in human monocytes, we infected monocytes in the presence or absence ofthis molecule. At a concentration of 2.0 mg/ml, apolactoferrin markedly inhibited L. pneumophila intracellular multiplication ( Fig. 1 A) . The inhibitory effect was not due to a toxic effect of apolactoferrin on monocytes because apolactoferrintreated monocyte monolayers were intact after 4 d of culture and the monocytes were viable by trypan blue exclusion (data not shown).
The inhibitory effect ofapolactoferrin was dependent upon its iron-unsaturated state. In contrast to apolactoferrin, ironsaturated lactoferrin, at a concentration of 6 mg/ml, had no effect on L. pneumophila multiplication (Fig. 1 B) .
The inhibitory effect of apolactoferrin on L. pneumophila intracellular multiplication is due to its interaction with the monocyte and not to a direct toxic effect on the bacterium. Apolactoferrin has been found to kill gram-negative bacteria under hypoosmolar conditions (22, 23) . In previous studies by other investigators, apolactoferrin has been found to exert a bactericidal effect against broth-grown (but not agar-grown) L. pneumophila suspended in water (24, 25) . Although the experimental conditions of these studies were very different from ours, e.g., we used agar-grown bacteria and held them under physiologic conditions (isosmolar medium buffered to pH 7.4, 37°C, 5% C02-95% air), we performed additional experiments to explore the possibility that apolactoferrin was directly toxic to L. pneumophila under our experimental conditions. First, we incubated L. pneumophila in tissue culture medium with and without apolactoferrin (3 mg/ml) for 3 d and assessed bacterial survival. Apolactoferrin had no influence on the survival of L. pneumophila in tissue culture medium (data not shown). Second, we examined the possibility that apolactoferrin exerted an effect on the bacteria which subsequently rendered them more susceptible to killing or less able to multiply in the monocyte. We preincubated the bacteria with or without apolactoferrin for 24 h, washed them, added them to monocytes, and assessed their capacity to multiply. Preincubation of L. pneumophila with apolactoferrin had no influence on the capacity of the bacteria to multiply in monocytes (Fig. 2 A) . In contrast, when L. pneumophila from the same stock were added to replicate monocyte monolayers in the same experiment, but in the pres- Figure 1 . Apolactoferrin inhibits L. pneumophila intracellular multiplication in nonactivated human monocytes but iron-saturated lactoferrin has no effect. Monocytes in monolayer culture were incubated with apolactoferrin (2 mg/ml) or control medium (RPMI containing 20% NHS) (A) or iron-saturated lactoferrin (6 mg/ml) or control medium (B ence of apolactoferrin, L. pneumophila intracellular multiplication was inhibited (Fig. 2 B) . These results indicated that apolactoferrin is not directly toxic to L. pneumophila and that it exerts its inhibitory effect on L. pneumophila intracellular growth via an interaction with the monocyte. Thus, apolactoferrin appears to limit the availability of iron to intracellular L. pneumophila and thereby restrict bacterial multiplication in a manner similar to deferoxamine in previous studies (8) .
Iron-saturated lactoferrin reverses, whereas apolactoferrin enhances, the capacity of activated monocytes to inhibit L. pneumophila intracellular multiplication. IFNy-activated monocytes inhibit L. pneumophila intracellular multiplication by limiting the availability of iron to the bacterium (8) . To determine if iron lactoferrin could supply iron to L. pneumophila and reverse the inhibitory effect of activation, we activated monocytes with IFNy in the presence ofvarious concentrations ofiron lactoferrin, infected them with L. pneumophila, and assayed intracellular multiplication (Fig. 3) .
Iron-lactoferrin at a concentration of 6 mg/ml reversed the capacity of IFNy-activated monocytes to inhibit L. pneumophila multiplication. This neutralizing effect ofiron lactoferrin on monocyte activation was dose dependent (Fig. 3) . At a concentration of 2.0 and 0.7 mg/ml, iron lactoferrin partially reversed monocyte activation. At concentrations of0.2 mg/ml or less, iron lactoferrin had little or no effect on the capacity of activated monocytes to inhibit L. pneumophila multiplication.
To confirm that the effect ofiron lactoferrin was due to iron and not lactoferrin, we compared the effect of iron lactoferrin to that of apolactoferrin on the capacity of IFNy-activated monocytes to inhibit L. pneumophila multiplication (Fig. 4) . At concentrations ofapolactoferrin > 2.0 mg/ml, the activated monocytes did not remain adherent to the tissue culture wells, so we studied the effects of iron-lactoferrin and apolactoferrin at a concentration of 2.0 mg/ml. Whereas iron-lactoferrin partially reversed the inhibitory effect ofactivation, apolactoferrin had no such effect and in fact enhanced the inhibitory effect of IFNy. In these experiments, the apolactoferrin-treated monolayers remained intact throughout the course of the infection, and the monocytes were viable at 4 d by trypan blue exclusion. These experiments show that iron-lactoferrin is capable of reversing the inhibitory effect of IFNy activation on L. pneumophila intracellular multiplication and that this effect is due to iron and not the lactoferrin molecule. These experiments also show that apolactoferrin enhances the capacity of IFNyactivated monocytes to inhibit L. pneumophila intracellular multiplication.
The capacity ofiron-lactoferrin to reverse the inhibitory effect of activated monocytes on L. pneumophila intracellular multiplication is dependent upon its degree of iron saturation and not only its total iron content. To determine the influence of iron-saturation on the capacity of iron-lactoferrin to reverse the inhibitory effect of activated monocytes, we activated monocytes with IFNy in the presence of 3 mg/ml lactoferrin that was 90, 51, or 28% iron saturated, infected them with L. pneumophila, and assayed intracellular multiplication. The capacity of iron-lactoferrin to reverse the inhibitory effect of monocyte activation was dependent upon its percent saturation (90 > 51 > 28%) (Fig. 5 A) .
The greater capacity of more saturated iron-lactoferrin to reverse monocyte activation against L. pneumophila might simply reflect its higher iron content. In addition, the ratio ofsaturated to unsaturated lactoferrin might be an important factor. To examine this possibility, we activated monocytes with IFNy in the presence of three different iron lactoferrin preparations containing nearly comparable amounts of total iron but two very different ratios of saturated:unsaturated lactoferrin (Fig.  5 B) . The preparation containing a high ratio (9:1) of saturated:unsaturated lactoferrin (3 mg/ml of 90% iron lactoferrin) had a significantly greater capacity to reverse monocyte activation than two preparations containing a low ratio (-1:1) of saturated:unsaturated lactoferrin (3 mg/ml of 90% iron lac-1106 T. F. Byrd ratios of saturated:unsaturated lactoferrin, 9:1 (3 mg/ml of 90% iron-lactoDays after infection ferrin) or 1:1 (3 mg/ml of 90% iron-lactoferrin plus 3 mg/ml apolactoferrin; 6 mg/ml of 51% iron-lactoferrin). In A and B, one set of IFNy-treated monocytes were incubated without lactoferrin. After 24 h, all cultures were infected with L. pneumophila, and CFU were determined daily. Data are mean±SEM for triplicate cultures. toferrin plus 3 mg/ml of apolactofenin; 6 mg/ml of 51% ironlactoferrin). Viewed another way, apolactoferrin neutralized the capacity of highly saturated (90%) iron-lactoferrin to reverse monocyte activation against L. pneumophila. Thus, the percent iron saturation of lactofernin and not just its total iron content is an important determinant of its capacity to reverse monocyte activation against L. pneumophila.
Iron-lactoferrin reverses the inhibitory effect of monocyte activation by a transferrin receptor-independent route. In the assays described above, monocytes were cultured in the presence of 20% normal human serum which contains transferrin. Although lactoferrin has a 300-fold higher affinity for iron than transferrin (26) the possibility remained that some exchange of iron from lactoferrin to transferrin occurred under these tissue culture conditions and that the effect of iron lactoferrin was mediated by iron-transferrin. To explore this possibility, we studied the effect of lactoferrin on monocyte activation in the absence of serum, and therefore of transferrin. We activated monocyte monolayers with IFNy in serumless medium, infected them with preopsonized L. pneumophila in the complete absence ofserum, and assayed L. pneumophila intracellular multiplication (Fig. 6) . In serumless medium, as in medium containing serum, IFNy-activated monocytes inhibited L. pneumophila intracellular multiplication. Iron-saturated lactoferrin (6 mg/ml) completely reversed this inhibitory effect. This experiment shows that iron-saturated lactoferrin can enter the monocyte via a transferrin receptor-independent route and supply iron to intracellular L. pneumophila.
The nonphysiologic iron chelates FeNTA andferric ammonium citrate reverse the capacity ofactivated monocytes to inhibit L. pneumophila intracellular multiplication. We next explored whether nonphysiologic iron chelates that enter monocytes independently of the transferrin-transferrin receptor or lactoferrin-lactoferrin receptor pathways can reverse the capacity of IFNy-activated monocytes to inhibit L. pneumophila multiplication. We infected monocytes with L. pneumophila in the presence or absence of the nonphysiologic iron chelates FeNTA, ferric ammonium citrate, or ferric pyrophosphate and assayed intracellular multiplication (Fig. 7) .
At an iron concentration of 8 gg/ml, all three iron chelates partially reversed the inhibitory effect ofIFNy-activated monocytes on L. pneumophila multiplication (Fig. 7 A) . At an iron concentration of 25 gg/ml, FeNTA and ferric ammonium citrate completely reversed the inhibitory effect of IFN'y-activated monocytes, but ferric pyrophosphate still only partially reversed the inhibitory effect (Fig. 7 B) . The differences among these iron chelates in reversing the effect of monocyte activation probably reflect differences in their solubility at neutral pH and consequently their uptake by monocytes.
As was the case with iron lactoferrin, the neutralizing effect of FeNTA on monocyte activation was dose dependent ( At iron concentrations of 0.3 gg/ml or less, ferric nitrilotriacetate had little or no effect on the capacity of activated monocytes to inhibit L. pneumophila multiplication.
To confirm that the effect of FeNTA was due to iron and not to nitrilotriacetate, we compared the effect of FeNTA to that of NTA on the capacity of IFNy-activated monocytes to inhibit L. pneumophila multiplication (Fig. 9) . Whereas FeNTA completely reversed the inhibitory effect of activation, NTA had no effect. Analysis by trypan blue exclusion showed that NTA-treated monolayers were intact and viable at 4 d.
These experiments demonstrated that the nonphysiologic iron chelates FeNTA and ferric ammonium citrate are capable of reversing the inhibitory effect of IFN-y on L. pneumophila intracellular multiplication, and that at least in the case of FeNTA this effect is due to iron and not nitrilotriacetate.
The nonphysiologic iron chelates enter the monocyte and reverse the inhibitory effect ofmonocyte activation by a transferrin receptor-independent route. In the assays described above, monocytes were cultured in the presence of20% normal human serum, which contains transferrin. The amount ofironsaturated transferrin in 20% serum, -0.2 mg/ml, is below the level that even partially reverses monocyte activation against L. pneumophila. However, both FeNTA and ferric ammonium citrate can donate iron to transferrin, raising the possibility that the effect of these iron chelators may at least in part be mediated by the transferrin-transferrin receptor endocytic pathway. To explore this possibility, we studied the effect of the nonphysiologic iron chelates on monocyte activation in the absence of serum. We cultured monocytes in serumless media, 107 - Figure 9 infected them with preopsonized L. pneumophila in the complete absence ofserum, and assayed L. pneumophila intracellular multiplication (Fig. 10) .
In the absence of serum, as in its presence, ferric ammonium citrate, at a concentration of 25 Ag iron/ml, completely reversed the inhibitory effect of IFNy-activated monocytes on L. pneumophila intracellular multiplication. Experiments using FeNTA could not be carried out under the serumless conditions employed, because this chelate was unstable and formed iron precipitates in the serumless medium. These experiments show that the nonphysiologic iron chelate ferric ammonium citrate can enter the monocyte via a transferrin receptor-independent route and supply iron to intracellular L. pneumophila.
Discussion
This study demonstrates that unsaturated lactoferrin, an ironbinding protein postulated to play a role in host defense against extracellular pathogens (1, 13, 22, 27) , can inhibit L. pneumophila intracellular multiplication in nonactivated monocytes.
In addition, this study shows that lactoferrin can reverse or enhance the capacity of IFNy-activated human monocytes to inhibit L. pneumophila intracellular multiplication depending on its degree of iron saturation.
Lactoferrin is an iron-binding protein with a high degree of homology to transferrin (26) . It is found in the specific granules ofneutrophils (28, 29) and in mucosal secretions (30) including bronchial secretions (31) (32) (33) . In its unsaturated form, it has been found to have either a bacteriostatic or a bactericidal effect against a variety ofextracellular bacteria in vitro (1, 13, 22, 23, 27) . At sites of inflammation, such as occurs at infected sites in the body, unsaturated lactoferrin is released by the specific granules of neutrophils into the extracellular environment. At the acidic pH often found at sites of inflammation, free iron is present because transferrin is unable to bind and hold iron under acidic conditions. As lactoferrin has a high affinity for iron under acidic conditions it can bind this free iron, rendering it unavailable to pathogenic microorganisms treated monocytes were Days after infection additionally incubated with control medium or ferric ammonium citrate (25 fig iron/ml) . After 24 h, all cultures were infected with L. pneumophila, and CFU were determined daily. Data are mean±SEM for triplicate cultures. (34) . Iron-lactoferrin is taken up by mononuclear phagocytes via receptors with specificity for lactoferrin (17, 18) . By this mechanism, lactoferrin contributes to a localized hypoferremia at sites ofinfection or inflammation, and it may also contribute to the systemic hypoferremia seen in these states (14) .
The release of iron from lactoferrin within the mononuclear phagocyte appears to involve a different mechanism than the release of iron from transferrin. In the case of transferrin, endocytized iron transferrin enters a distinct, mildly acidic endosomal compartment within the cell where it releases iron and is then recycled back to the cell surface (15, 16) . Whereas iron-lactoferrin also cycles through a mildly acidic endosomal compartment, it does not release iron under this condition.
Iron is released from lactoferrin when a portion ofthe endocytized lactoferrin enters the lysosomal compartment and is degraded (10).
Although the incorporation ofiron into the monocyte from iron-lactoferrin would appear to be less efficient than that from iron-transferrin, the kinetics of L. pneumophila multiplication in the presence of iron-transferrin (8) (35) . The evidence that iron from both lactoferrin and transferrin enters this pool is that iron entering through both these pathways is incorporated into intracellular ferritin (10-12, 35, 36 (8) . This may reflect more efficient endocytosis of lactoferrin because the affinity of the lactoferrin receptor for apolactoferrin is much greater than the affinity of the transferrin receptor for apotransferrin (17, 18, 37) . In addition, whereas IFNy activation downregulates the expression of monocyte transferrin receptors (8) , recent data suggests that IFNy has no effect on lactoferrin receptor expression (17) . Moreover, lactoferrin may bind iron more tightly than transferrin under acidic conditions within the cell. Apolactoferrin may consequently exert an inhibitory effect on L. pneumophila growth by chelating iron in the labile iron pool of the host cell and thereby deprive the bacteria of iron. Simi-In our study, iron lactoferrin concentrations of 0.7 and 2.0 mg/ml partially, and 6 mg/ml completely reversed monocyte activation against L. pneumophila, and apolactoferrin concentrations of 2.0 mg/ml inhibited L. pneumophila intracellular multiplication. Whereas the local concentrations oflactoferrin at sites of inflammation are not known, milligrams-per-milliliter concentrations seem likely given that concentrations of lactoferrin in human plasma during infection can exceed 0.2 mg/ml (38) . PMN are prominent in acute bacterial infection of the lung, and in an experimental murine model of pneumonia, increased concentrations of lactoferrin were demonstrated in lung lavage fluid, primarily as a result of neutrophil degranulation (39, 40) . PMN are also prominent in L. pneumophila infection of the lung, which is characterized histologically by an initial influx of PMN followed by an influx of mononuclear phagocytes, such that most established cases of pneumonia demonstrate a mix of neutrophils and mononuclear phagocytes (41) . As already noted, lactoferrin is not only released by neutrophils (14) , it is also synthesized by bronchial glands in the respiratory tract (30) (31) (32) (33) and is present in bronchoalveolar lavage fluid (42, 43) . Epithelial cell-derived lactoferrin appears to be responsible for much of the lactoferrin present in the lower respiratory tract of normal human subjects and patients with chronic bronchitis (44) . In patients with pulmonary diseases such as cystic fibrosis and bronchitis, lactoferrin is present in pooled pulmonary secretions in concentrations as high as 1.0-2.5 mg/ml (32, 33) . Thus, it seems conceivable that in a L. pneumophila pneumonic infiltrate, lactoferrin from neutrophils and bronchial secretions attains concentrations sufficient to influence monocyte activation in our study.
The capacity of lactoferrin to mediate growth of L. pneumophila in mononuclear-lphagocytes is dependent upon not only its iron content but also its percent iron saturation. Thus, in our study, highly iron-saturated lactoferrin strongly reversed monocyte activation against L. pneumophila, whereas poorly iron-saturated lactoferrin in an amount that had an equivalent total content of iron did not. These results imply that the net delivery of iron by lactoferrin into the mononuclear phagocyte is the result of an equilibrium between iron lactoferrin molecules entering the cell and releasing iron, and apolactoferrin molecules entering the cell, binding iron, and removing it from the cell.
Our data suggest that lactoferrin, when released at sites of inflammation in the L. pneumophila-infected lung, may augment or impede host defense against L. pneumophila depending upon its degree of iron saturation. Information on the percent saturation of lactoferrin in the L. pneumophila-infected lung is not available. When initially released by neutrophils, lactoferrin has been reported to be 8% saturated with iron (14) . The percent iron saturation oflactoferrin released by other cell types at mucosal surfaces is not known. Nor is it known how rapidly apolactoferrin acquires iron at sites of inflammation. Consequently, whether lactoferrin acts in a way that enhances or is counterproductive to host defense against L. pneumophila is not clear. Our study demonstrates that, in addition to iron-transferrin and iron-lactoferrin, nonphysiologic iron chelates including FeNTA can supply iron to L. pneumophila and neutralize the capacity of activated monocytes to inhibit L. pneumophila intracellular multiplication. Interestingly, FeNTA does not necessarily substitute for iron-transferrin or iron-lactoferrin in other situations. Whereas iron-transferrin, iron-lactoferrin, and FeNTA all increase the intracellular level of lymphocyte iron, only iron transferrin or iron lactoferrin provides iron in a form that allows proliferation of stimulated lymphocytes to occur (45, 46) . Similarly, iron transferrin but not FeNTA stimulates the proliferation and differentiation of renal tubular cells (47) . This may reflect different distributions and activities ofphysiologic and nonphysiologic iron compounds in cells. Along this line, Chang cells incorporate iron when treated with iron-transferrin or FeNTA but distribute the iron differently intracellularly (48) .
In our study, all three nonphysiologic iron compounds studied at least partially neutralized monocyte activation against L. pneumophila. FeNTA was the most effective compound in that it almost completely reversed activation at 8 ,ug iron/ml. Ferric ammonium citrate was the next most effective compound; it was only partially effective at 8 ug iron/ml but it completely reversed activation at 25 ,ug iron/ml. Ferric pyrophosphate was the least effective, only partially reversing activation even at 25 jg iron/ml. The differences among these compounds may reflect differences in their solubility properties. FeNTA, the most effective compound, has unique solubility properties among iron chelates. While most iron chelates polymerize at neutral or alkaline pH, FeNTA remains fully soluble in this pH range (20) . Consequently, it remains highly soluble at the near neutral pH (7.4) of tissue culture media.
Our The mechanism by which nonphysiologic iron chelates enter the cell in the absence of physiologic iron-binding proteins is unclear. One mechanism might simply be fluid phase endocytosis. Another mechanism is suggested by studies of iron transport into hepatocytes indicating that nontransferrinbound iron is transported into these cells by a membrane carrier for iron, and that this process is driven by the membrane potential difference between the interior and exterior of the cell (49) .
Our study confirms the central role of iron in IFNymediated monocyte activation against L. pneumophila. Our finding that a variety ofiron compounds, both physiologic and nonphysiologic, can reverse monocyte activation against L. pneumophila, and that a nonphysiologic iron chelate can reverse activation even under serumless conditions, emphasizes that iron, and not its carrier molecule, is responsible for the 1110 neutralizing effect of these iron compounds on monocyte activation.
Our study suggests a potential role for PMN, which are prominent at sites of infection in the lungs of patients with Legionnaires' disease, in host defense against L. pneumophila. Previous studies from this laboratory have indicated that PMN lack the capacity to kill appreciable numbers of L. pneumophila even in the presence of specific antibody and complement (50) . However, the current study provides a potential indirect role for PMN in host defense against L. pneumophila: providing infected mononuclear phagocytes with apolactoferrin and thereby enabling them to inhibit L. pneumophila intracellular multiplication. Consistent with this idea, a previous study has demonstrated that peritoneal macrophages from mice infected intraperitoneally with various mycobacteria contain lactoferrin, evidently derived from PMN, and that the addition of granulocytic extract to peritoneal macrophages infected with mycobacteria enhances their capacity to restrict mycobacterial growth in vitro (51) .
In a broader sense, our study supports the concept that PMN and mononuclear phagocytes may cooperate in host defense against intracellular parasites and other pathogens. PMN or their granule products have been reported to enhance the antimicrobial capacity of mononuclear phagocytes against a variety of pathogens in addition to L. pneumophila and mycobacteria. These include Toxoplasma gondii (52) , Trypanosoma cruzi (53) , Staphylococcus aureas (54) , and Candida albicans (55) . In addition to apolactoferrin, eosinophil peroxidase has been implicated as playing a role in PMN-mononuclear phagocyte cooperation; mononuclear phagocytes have been shown to have an enhanced capacity to kill eosinophil peroxidasecoated T. gondii, T. cruzi, and S. aureus (52) (53) (54) .
